Quantcast Cold Antibodies - Immunohematology and Blood Banking II

Share on Google+Share on FacebookShare on LinkedInShare on TwitterShare on DiggShare on Stumble Upon
Custom Search
(2)  Variation in the strength of the antigen. Some antigens that do not show
dosage in terms of zygosity may vary in strength on cells from different individuals. The
antigens most notable for this are P1, Sda, Lea, Leb, and I. Sometimes diminished
antigenic strength can be related to disease, or to the length of time that the cell
suspension has been stored.
a. Background. These antibodies react best at room temperature (RT) and
below, while reactions after 37C incubation and with AGT are negative or weakly
positive. Some cold agglutinating antibodies, notably anti-I, anti-lH, and anti-H, bind
complement following the antigen-antibody interaction at low temperatures; subsequent
37C incubation may cause the antibody to elute from the cell, but the attached
complement remains, and produces a positive reaction when antiglobulin serum is
added. An antibody displaying these characteristics in the screening test or in
crossmatches should be tested at 18C and/or 4C with specially selected cells, such as
cord cells.
b. Cold Autoabsorption to Remove Cold-Reactive Autoantibody.
(1)  When a strong, cold, autoantibody is present, meaningful
antibody-screening and compatibility studies cannot be done until the autoantibody is
removed. This can be done with the patient's untreated or enzyme-treated cells.
Enzyme pretreatment results in faster antibody removal, and is more effective with very
high-titered autoantibodies. Untreated autoabsorption is usually satisfactory for
removing low-level activity.
(2)  Some alloantibody may also be removed by the Matuhasi-Ogata
phenomenon, or by transfused cells in the circulation. In recently transfused patients,
when autoabsorption might result in removing alloantibody activity, the
antibody-screening test and compatibility tests should be done at 37C, using serum
from a blood sample clotted at 37C and kept at that temperature until the serum is
removed. This permits detection of antibodies active at 37C, and by AGT, but not
cold-reactive alloantibodies.
(a) STEP 1. Obtain a blood specimen from the patient. At the bedside
draw two specimens of blood, one in a tube immediately placed in ice, the other in a
tube containing anticoagulant and incubate it at once at 37C. To do this, bring a
heated block, water bath, or vacuum jug of 37C water to the patient's bedside. The
tube may also be transported in an inside pocket.
(b) STEP 2. Allow the first (iced) specimen to clot in the refrigerator.
Separate the serum by centrifuging in ice-filled cups or a refrigerated centrifuge.
Immediately remove the serum from the clot.

Medical News
Women, poor, uninsured face higher risk of psychological distress: CDC
(HealthDay)—Women, people with chronic medical conditions, the poor and those...
Higher disease burden for patients with fibromyalgia
(HealthDay)—Patients with fibromyalgia (FM) have a higher disease burden than...
House call primary care practices vary substantially
(HealthDay)—Home-based primary care practices vary in terms of size and...
Oil and gas industry worker death rate down by a third
(HealthDay)—Even as the oil and gas extraction industry in the...
Teen drivers a danger to others on the road, report warns
(HealthDay)—Teen drivers are a threat to everyone on the road,...
Study: Chimps teach people a thing or two about HIV resistance
I, personally, have never had trouble distinguishing a human being...
Research links impulsivity and binge eating
Do you get impulsive when you're upset? If so, this...
Parents feel racial socialization may help minority children succeed in school
A child's ability to succeed academically is one of the...
CDC: 150 possibly had contact with Lassa fever victim
Federal and New Jersey health officials have identified more than...
Census: No. of Americans on assistance may be leveling off
The once-increasing number of Americans getting some kind of public...
Even when we're resting, our brains are preparing us to be social
Even when we're resting, our brains are preparing us to...
Patients Resist 'Less Is More,' a MedPage Today Survey
(MedPage Today) -- Physicians limiting "low-value" tests find patients need...
Less Is More: Evaluating Screenings
(MedPage Today) -- This is what the benefits and risks...
Portable finger-probe device can successfully measure liver function in potential organ donors
A portable, finger-probe device successfully measured liver function in brain...
Brain training induces lasting brain, mental health gains for veterans, civilians with brain injury
In the first study of its kind, veterans and civilians...
The new normal? Addressing gun violence in America
Article Spotlight features summaries written in collaboration with authors of...
The Ongoing Quest for Quality
(MedPage Today) -- Fred N. Pelzman, MD, ponders how quality...
HIV Co-Infection: Hepatitis C
(MedPage Today) -- 10 days, 10 questions: Day 8 --...
ASCO: MEDI4736 combined with tremelimumab results in acceptable toxicity in NSCLC patients
Advanced non-small cell lung cancer (NSCLC) patients have few effective...
ASCO: Nivolumab treatment in melanoma patients has manageable safety profile
The monoclonal antibody nivolumab has shown promise as a therapeutic...

Privacy Statement - Copyright Information. - Contact Us

comments powered by Disqus

Integrated Publishing, Inc.
9438 US Hwy 19N #311 Port Richey, FL 34668

Phone For Parts Inquiries: (727) 755-3260
Google +